[ CAS No. 758684-29-6 ] {[proInfo.proName]}

Name: 758684-29-6|Methyl 3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate|97%
Brand: Ambeed
SKU: A103531
Price: 16.0 USD
Availability: InStock
Rating: 99 (27 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 758684-29-6

Structure of 758684-29-6 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 758684-29-6 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 758684-29-6 ]

SDS Specification

Alternatived Products of [ 758684-29-6 ]

Product Details of [ 758684-29-6 ]

CAS No. :	758684-29-6	MDL No. :	MFCD08544342
Formula :	C₁₀H₁₁NO₃	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	CCROCSXSFACGHR-UHFFFAOYSA-N
M.W :	193.20	Pubchem ID :	16244461
Synonyms :

Calculated chemistry of [ 758684-29-6 ]

Physicochemical Properties

Num. heavy atoms :	14
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.3
Num. rotatable bonds :	2
Num. H-bond acceptors :	3.0
Num. H-bond donors :	1.0
Molar Refractivity :	54.34
TPSA :	47.56 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.41 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.12
Log Po/w (XLOGP3) :	1.5
Log Po/w (WLOGP) :	0.71
Log Po/w (MLOGP) :	0.97
Log Po/w (SILICOS-IT) :	1.65
Consensus Log Po/w :	1.39

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-2.17
Solubility :	1.31 mg/ml ; 0.00679 mol/l
Class :	Soluble
Log S (Ali) :	-2.11
Solubility :	1.51 mg/ml ; 0.00783 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-2.82
Solubility :	0.292 mg/ml ; 0.00151 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	2.07

Safety of [ 758684-29-6 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H332-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 758684-29-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 758684-29-6 ]
Downstream synthetic route of [ 758684-29-6 ]

[ 758684-29-6 ] Synthesis Path-Upstream 1~7

1
[ 106-93-4 ]
[ 536-25-4 ]
[ 758684-29-6 ]

Yield	Reaction Conditions	Operation in experiment
73%	With potassium carbonate In N,N-dimethyl-formamide at 70℃;	Step 2. A solution of 3-amino-4-hydroxy-benzoic acid methyl ester (4.2 g, 25.4 mmol) in dimethylformamide (85 mL) was treated with K₂CO₃(14.2 g, 102.9 mmol, 4 equiv.) and 1,2-dibromoethane (19.3 g, 102.9 mmol, 4 equiv.). The mixture was stirred at 70° C. overnight, then filtered to remove the solids. The filtrate was removed under vacuo, and the residue was purified by flash chromatography (heptane/ethyl acetate gradient) to yield 3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylic acid methyl ester, 3.65 g (73percent) as a light yellow solid, MS (ISP): m/e=235.1 (M+CH₃C^N+.); δ_H(300 MHz; CDCl₃) 7.36 (1H, dd, J=8.5, 2.0), 7.30 (1H, d, J=2.0), 6.78 (1H, d, J=8.5), 4.30 (2H, m); 3.85 (3H, s), 3.43 (2H, m).

Reference： [1] Patent: US2007/191603, 2007, A1, . Location in patent: Page/Page column 25
[2] Patent: US2009/176775, 2009, A1, . Location in patent: Page/Page column 30
[3] Patent: EP2172453, 2010, A1, . Location in patent: Page/Page column 15-16

2
[ 604756-32-3 ]
[ 758684-29-6 ]
[ 915160-96-2 ]

Reference： [1] Patent: US2007/10670, 2007, A1, . Location in patent: Page/Page column 97
[2] Patent: US2008/64871, 2008, A1, . Location in patent: Page/Page column 59

3
[ 604756-32-3 ]
[ 758684-29-6 ]

Reference： [1] Bioorganic and Medicinal Chemistry, 2006, vol. 14, # 24, p. 8219 - 8248
[2] Patent: US2008/305169, 2008, A1,
[3] Patent: US2006/35939, 2006, A1, . Location in patent: Page/Page column 25

4
[ 99-42-3 ]
[ 758684-29-6 ]

Reference： [1] Bioorganic and Medicinal Chemistry, 2006, vol. 14, # 24, p. 8219 - 8248
[2] Patent: US2008/64871, 2008, A1,

5
[ 616-82-0 ]
[ 758684-29-6 ]

Reference： [1] Bioorganic and Medicinal Chemistry, 2006, vol. 14, # 24, p. 8219 - 8248
[2] Patent: US2008/64871, 2008, A1,

6
[ 83785-14-2 ]
[ 758684-29-6 ]

Reference： [1] Bioorganic and Medicinal Chemistry, 2006, vol. 14, # 24, p. 8219 - 8248

7
[ 536-25-4 ]
[ 758684-29-6 ]

Reference： [1] Patent: US2008/64871, 2008, A1,

[ 758684-29-6 ] Synthesis Path-Downstream 1~45

1
[ 758684-29-6 ]
[ 918789-44-3 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2006,vol. 14,p. 8219 - 8248

2
[ 604756-32-3 ]
[ 758684-29-6 ]

Yield	Reaction Conditions	Operation in experiment
	In tetrahydrofuran; methanol;	Step 4 Production of methyl 3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate Methyl 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate (1.009 g) was added to borane-tetrahydrofuran complex (1M tetrahydrofuran solution, 11 mL) under ice-cooling, and the mixture was stirred with heating at 70 C. for 3.5 hrs. Methanol (3 mL) was added dropwise and the mixture was further stirred with heating for 3 hrs. The mixture was extracted with ethyl acetate, and the obtained ethyl acetate layer was washed with saturated brine, and dried over anhydrous sodium sulfate. The solvent was evaporated, and the obtained residue was purified by silica gel chromatography (chloroform-methanol=98:2) to give the title compound (281.3 mg) as a pink solid and (3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)methanol (413.8 mg) as an oil.
	With borane-THF; In tetrahydrofuran; for 1.5h;Heating / reflux;	Methyl 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate (3 g) obtained in the preceding step was dissolved in tetrahydrofuran (50 mL), and 1 M borane/tetrahydrofuran solution (17.4 mL) was added, and the mixture was refluxed under stirring for 1.5 hours. The reaction mixture was ice-cooled, 6 M hydrochloric acid was added under stirring until pH was adjusted to 2, stirring was then continued for 1 hour. The reaction mixture was partitioned by ethyl acetate and sodium bicarbonate aqueous solution, and the ethyl acetate layer was washed with a saturated brine, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel chromatography (hexane:ethyl acetate=3:1) to obtain the title compound (2 g).

Reference： [1]Bioorganic and Medicinal Chemistry,2006,vol. 14,p. 8219 - 8248
[2]Patent: US2008/305169,2008,A1
[3]Patent: US2006/35939,2006,A1 .Location in patent: Page/Page column 25

3
[ 758684-29-6 ]
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3,4-dihydro-2H-1,4-benzoxazine-6-carboxamide fumarate [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2006,vol. 14,p. 8219 - 8248

4
3-amino-4-methoxycarbonylmethoxy-benzoic acid methyl ester [ No CAS ]
[ 758684-29-6 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2006,vol. 14,p. 8219 - 8248

5
[ 99-42-3 ]
[ 758684-29-6 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2006,vol. 14,p. 8219 - 8248
[2]Patent: US2008/64871,2008,A1

6
[ 616-82-0 ]
[ 758684-29-6 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2006,vol. 14,p. 8219 - 8248
[2]Patent: US2008/64871,2008,A1

7
[ 83785-14-2 ]
[ 758684-29-6 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2006,vol. 14,p. 8219 - 8248

8
[ 604756-32-3 ]
[ 758684-29-6 ]
[ 915160-96-2 ]

Yield	Reaction Conditions	Operation in experiment
	With borane-THF; In tetrahydrofuran; methanol; at 0 - 70℃; for 6.5h;	Step 4 Production of methyl 3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate Methyl 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate (1.009 g) was added to borane-tetrahydrofuran complex (1M tetrahydrofuran solution, 11 mL) under ice-cooling, and the mixture was stirred with heating at 70 C. for 3.5 hrs. Methanol (3 mL) was added dropwise and the mixture was further stirred with heating for 3 hrs. The mixture was extracted with ethyl acetate, and the obtained ethyl acetate layer was washed with saturated brine, and dried over anhydrous sodium sulfate. The solvent was evaporated, and the obtained residue was purified by silica gel chromatography (chloroform-methanol=98:2) to give the title compound (281.3 mg) as a pink solid and (3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)methanol (413.8 mg) as an oil.
		Step 4 Production of methyl 3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate Methyl 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate (1.009 g) was added to borane-tetrahydrofuran complex (1M tetrahydrofuran solution, 11 mL) under ice-cooling, and the mixture was stirred with heating at 70 C. for 3.5 hrs. Methanol (3 mL) was added dropwise and the mixture was further stirred with heating for 3 hrs. The mixture was extracted with ethyl acetate, and the obtained ethyl acetate layer was washed with saturated brine, and dried over anhydrous sodium sulfate. The solvent was evaporated, and the obtained residue was purified by silica gel chromatography (chloroform-methanol=98:2) to give the title compound (281.3 mg) as a pink solid and (3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)methanol (413.8 mg) as an oil.

Reference： [1]Patent: US2007/10670,2007,A1 .Location in patent: Page/Page column 97
[2]Patent: US2008/64871,2008,A1 .Location in patent: Page/Page column 59

9
[ 758684-29-6 ]
[ 59595-92-5 ]
methyl 4-(3,5-dichloro-4-hydroxybenzoyl)-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In ethyl acetate; at 0 - 80℃;	Step 5 Production of methyl 4-(3,5-dichloro-4-hydroxybenzoyl)-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate Methyl 3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate (81.2 mg) was dissolved in ethyl acetate (3 mL), 3,5-dichloro-4-hydroxybenzoyl chloride (108.3 mg) obtained in Step 1 of Example 3 was added under ice-cooling, and the mixture was stirred overnight at 80 C. The solvent was evaporated, and the obtained residue was purified by silica gel chromatography (chloroform-methanol=95:5) to give the title compound (167.8 mg) as a white amorphous solid.
	In ethyl acetate; at 0 - 80℃;	Step 5 Production of methyl 4-(3,5-dichloro-4-hydroxybenzoyl)-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate Methyl 3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate (81.2 mg) was dissolved in ethyl acetate (3 mL), 3,5-dichloro-4-hydroxybenzoyl chloride (108.3 mg) obtained in Step 1 of Example 3 was added under ice-cooling, and the mixture was stirred overnight at 80 C. The solvent was evaporated, and the obtained residue was purified by silica gel chromatography (chloroform-methanol=95:5) to give the title compound (167.8 mg) as a white amorphous solid.

Reference： [1]Patent: US2007/10670,2007,A1 .Location in patent: Page/Page column 97
[2]Patent: US2008/64871,2008,A1 .Location in patent: Page/Page column 59-60

10
[ 106-93-4 ]
[ 536-25-4 ]
[ 758684-29-6 ]

Yield	Reaction Conditions	Operation in experiment
73%	With potassium carbonate; In N,N-dimethyl-formamide; at 70℃;	Step 2. A solution of 3-amino-4-hydroxy-benzoic acid methyl ester (4.2 g, 25.4 mmol) in dimethylformamide (85 mL) was treated with K2CO3 (14.2 g, 102.9 mmol, 4 equiv.) and 1,2-dibromoethane (19.3 g, 102.9 mmol, 4 equiv.). The mixture was stirred at 70 C. overnight, then filtered to remove the solids. The filtrate was removed under vacuo, and the residue was purified by flash chromatography (heptane/ethyl acetate gradient) to yield 3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylic acid methyl ester, 3.65 g (73%) as a light yellow solid, MS (ISP): m/e=235.1 (M+CH3CN+.); deltaH (300 MHz; CDCl3) 7.36 (1H, dd, J=8.5, 2.0), 7.30 (1H, d, J=2.0), 6.78 (1H, d, J=8.5), 4.30 (2H, m); 3.85 (3H, s), 3.43 (2H, m).
	With potassium carbonate; In N,N-dimethyl-formamide; at 110℃; for 5h;	10.2: Methyl 3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate; 5.16 g of methyl 3-amino-4-hydroxybenzoate are dissolved in 100 ml of dimethylformamide in a 500 ml round-bottomed flask. 17.06 g of potassium carbonate and then 7.98 ml of dibromoethane are subsequently added. The reaction medium is heated at 110 C. with stirring for five hours. After evaporating the solvent, water and ethyl acetate are added. The aqueous phase is extracted three times with ethyl acetate. The organic phases are combined and then dried over magnesium sulfate and the solvent is evaporated under reduced pressure. The residue is chromatographed on silica gel with a heptane/ethyl acetate 6/4 mixture. 3.61 g of methyl 3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate are obtained.M+H+=194.3
	With potassium carbonate; In N,N-dimethyl-formamide; at 20 - 130℃;	To a solution of 4-hydroxy-3-nitrobenzoic acid (10.0 g) in methanol (100 ml), concentrated sulfuric acid (1 ml) was added and stirred at 80C for 19.5 hours. After the reaction mixture was concentrated, saturated aqueous sodium bicarbonate and ethyl acetate were added to the resulting residue. This mixture was stirred and the aqueous layer was then separated. The separated aqueous layer was diluted with 1M aqueous hydrochloric acid and extracted with ethyl acetate. The organic layer was washed sequentially with water and brine, and then dried over anhydrous sodium sulfate. After the desiccant was filtered off, the solvent was distilled off under reduced pressure to give methyl 4-hydroxy-3-nitrobenzoate (10.9 g) as a yellow solid. To a solution of methyl 4-hydroxy-3-nitrobenzoate thus obtained (10.9 g) in tetrahydrofuran:methanol (1:1, 100 ml), 10% palladium on activated carbon (550 mg) was added and stirred overnight under a hydrogen atmosphere at room temperature. After the reaction mixture was filtered through celite, the solvent was distilled off under reduced pressure to give methyl 3-amino-4-hydroxybenzoate (9.1 g) as a light-brown solid. To a solution of methyl 3-amino-4-hydroxybenzoate thus obtained (9.1 g) in N,N-dimethylformamide (80 ml), potassium carbonate (37.3 g) and 1,2-dibromoethane (14 ml) were added and stirred at 130C for 2 hours and then stirred overnight at room temperature. After insoluble materials were filtered off, the filtrate was diluted with ethyl acetate and washed with water. The organic layer was extracted with 6M aqueous hydrochloric acid, and the resulting aqueous layer was diluted with 8M aqueous sodium hydroxide and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and then filtered to remove the desiccant, followed by distilling off the solvent under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluting solvent: n-hexane:ethyl acetate = 10:1 to 5:1) to give the titled compound, i.e., methyl 3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate (7.10 g) as a pink solid. 1H NMR (300 MHz, CHLOROFORM-D) delta 3.39-3.47 (m, 2 H), 3.82-3.89 (m, 4 H), 4.26-4.34 (m, 2 H), 6.78 (d, J=8.4 Hz, 1 H), 7.29 (d, J=2.0 Hz, 1 H), 7.37 (dd, J=8.4, 2.0 Hz, 1 H).

Reference： [1]Patent: US2007/191603,2007,A1 .Location in patent: Page/Page column 25
[2]Patent: US2009/176775,2009,A1 .Location in patent: Page/Page column 30
[3]Patent: EP2172453,2010,A1 .Location in patent: Page/Page column 15-16

11
[ 758684-29-6 ]
[ 22952-32-5 ]
[ 946120-73-6 ]

Yield	Reaction Conditions	Operation in experiment
95%	With pyridine; In dichloromethane; at 20℃;	Step 3. To a solution of 5-chloro-2-methoxy-benzenesulfonyl chloride (4.7 g, 19.7 mmol, 1.05 equiv.) in dichloromethane (60 mL) and pyridine (25 mL) was added a solution of 3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylic acid methyl ester (3.6 g, 18.8 mmol, 1 equiv.) in dichloro-methane (60 mL). The mixture was stirred at room temperature overnight then the solvent was removed. The residue was purified by flash chromatography to yield 4-(5-chloro-2-methoxy-benzenesulfonyl)-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylic acid methyl ester as a pink solid, 7.12 g (95%), MS (ISP): m/e=398.0 (M+H+.); deltaH (300 MHz; CDCl3) 8.24 (1H, s), 8.07 (1H, s), 7.72 (1H, dd), 7.48 (1H, dd), 6.91 (1H, d), 6.89 (1H, d), 4.10 (2H, m), 3.91 (2H, m), 3.88 (3H, s), 3.63 (3H, s).

Reference： [1]Patent: US2007/191603,2007,A1 .Location in patent: Page/Page column 25

12
[ 758684-29-6 ]
[ 2402-77-9 ]
[ 873852-16-5 ]

Yield	Reaction Conditions	Operation in experiment
	With caesium carbonate; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl;tris-(dibenzylideneacetone)dipalladium(0); In toluene; at 80℃;	Step 5 Preparation of methyl 4-(3-chloropyridin-2-yl)-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate Methyl 3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate (1 g) obtained in the preceding step was dissolves in toluene (10 mL). 2,3-dichloropyridine (1.5 g), tris(dibenzylideneacetone) dipalladium (356 mg), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (242 mg) and cesium carbonate (1.42.53 g) were added in this order, and the mixture was heated at 80 C. under stirring overnight. After the reaction mixture was allowed to cool, ethyl acetate and water were added, insoluble substances were filtered off, and the obtained ethyl acetate layer was washed with a saturated brine, dried over anhydrous magnesium sulfate and concentrated. The obtained residue was purified by silica gel chromatography (hexane:tetrahydrofuran=3:1) to obtain the oily title compound (250 mg).

Reference： [1]Patent: US2006/35939,2006,A1 .Location in patent: Page/Page column 25

13
[ 758684-29-6 ]
[ 888730-48-1 ]
[ 59595-92-5 ]
methyl 4-(3,5-dichloro-4-hydroxybenzoyl)-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In methyl (4-hydroxy-3-nitro)benzoate; ethyl acetate;	Step 5 Production of methyl 4-(3,5-dichloro-4-hydroxybenzoyl)-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate Methyl 3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate (81.2 mg) was dissolved in ethyl acetate (3 mL), 3,5-dichloro-4-hydroxybenzoyl chloride (108.3 mg) obtained in Step 1 of Reference Example 3 was added under ice-cooling, and the mixture was stirred overnight at 80 C. The solvent was evaporated, and the obtained residue was purified by silica gel chromatography (chloroform-methanol=95:5) to give the title compound (167.8 mg) as a white amorphous solid.

Reference： [1]Patent: US2008/305169,2008,A1

14
[ 758684-29-6 ]
[ 150281-46-2 ]
[ 32315-10-9 ]
[ 1000686-67-8 ]

Yield	Reaction Conditions	Operation in experiment
		10.3: Methyl 4-[(3-(pyridin-3-yl)pyrrolidin-1-yl)carbonyl]-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate; 1.8 g of <strong>[758684-29-6]methyl 3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate</strong>, 93.2 ml of dichloromethane and 4.62 ml of diisopropylethylamine are placed in a 250 ml round-bottomed flask under a nitrogen atmosphere. 1.38 g of triphosgene are added at 0 C. and then the reaction mixture is left stirring at ambient temperature for three hours. 1.62 ml of diisopropylethylamine and 1.45 g of 3-(pyrrolidin-3-yl)pyridine are subsequently added and the reaction mixture is stirred for eighteen hours. A saturated aqueous sodium hydrogencarbonate solution and dichloromethane are added. The aqueous phase is extracted three times with dichloromethane. The organic phases are combined, washed with water and with a saturated aqueous sodium chloride solution and dried over sodium sulfate and then the solvent is evaporated under reduced pressure. The residue is chroratographed on silica gel with a dichloromethane/methanol 95/5 mixture. 2.39 g of methyl 4-[(3-(pyridin-3-yl)pyrrolidin-1-yl)carbonyl]-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate are obtained.Melting point=61 C., M+H+=368.3

Reference： [1]Patent: US2009/176775,2009,A1 .Location in patent: Page/Page column 30

15
[ 758684-29-6 ]
[ 75-03-6 ]
C₁₂H₁₅NO₃ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2009,vol. 19,p. 4292 - 4295

16
[ 758684-29-6 ]
E-4-aminoadamantan-1-ol [ No CAS ]
[ 530-62-1 ]
methyl 4-[(E-5-hydroxyadamantan-2-yl)carbamoyl]-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		To a solution of N,N'-carbonyldiimidazole (728 mg) and triethylamine (0.63 ml) in chloroform (20 ml), E-4-aminoadamantan-1-ol obtained in Reference Example 2 (500 mg) and N,N-dimethylformamide (8 ml) were added and stirred at room temperature for 1 hour. To the reaction mixture, <strong>[758684-29-6]methyl 3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate</strong> obtained in Reference Example 22 (867 mg) was added and heated under reflux for 1.5 hours, followed by stirring overnight at room temperature. The reaction mixture was then heated under reflux for an additional 8 hours. After cooling at room temperature, the reaction mixture was diluted with chloroform and washed with water. The organic layer was concentrated under reduced pressure, and the residue was diluted with ethyl acetate and washed sequentially with water, 1M aqueous hydrochloric acid, saturated aqueous sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate and then filtered to remove the desiccant, followed by distilling off the solvent under reduced pressure. The resulting residue was dissolved in chloroform and converted into a powder form by addition of diethyl ether and n-hexane, and the resulting crystal was collected by filtration to give the titled compound (Compound 20, 972 mg) as a light-brown powder. 1H NMR (300 MHz, CHLOROFORM-D) delta 1.47-1.83 (m, 9 H), 1.85-1.96 (m, 2 H), 2.10-2.23 (m, 3 H), 3.85-3.94 (m, 5 H), 3.95-4.03 (m, 1 H), 4.27-4.34 (m, 2 H), 5.61 (d, J=6.8 Hz, 1 H), 6.99 (d, J=8.7 Hz, 1 H), 7.75 (dd, J=8.70, 2.0 Hz, 1 H), 8.11 (d, J=2.0 Hz, 1 H).

Reference： [1]Patent: EP2172453,2010,A1 .Location in patent: Page/Page column 29

17
[ 758684-29-6 ]
[ 98-59-9 ]
[ 1309477-85-7 ]

Reference： [1]Journal of Medicinal Chemistry,2011,vol. 54,p. 3982 - 3986

18
[ 758684-29-6 ]
[ 1313994-05-6 ]

Yield	Reaction Conditions	Operation in experiment
62%	With palladium diacetate; In acetonitrile;	Step 8a: methyl 4-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (Intermediate 8a) To a stirred solution of compound 5-I (1 g, 3.8 mmol) in acetonitrile (40 mL) was added <strong>[758684-29-6]methyl 3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate</strong> (0.73 g, 3.8 mmol), Cs2CO3 (2.5 g, 7.6 mmol), Pd(OAc)2 (51 mg, 0.2 mmol) and Xanthophos (176 mg, 0.3 mmol) at room temperature. The reaction mixture was degassed with argon for 45 minutes and stirred for 16 h at 80 C. After completion of the reaction (monitored by TLC), the reaction mixture was filtered through a pad of celite and washed with DCM (100 mL) and the filtrate was washed with water (100 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. The crude compound was purified by washings with diethyl ether to afford compound 8a (880 mg, 62%) as brown solid. TLC: EtOAc (Rf: 0.3). 1H-NMR (CDCl3, 200 MHz): delta 8.64 (d, J=2.0 Hz, 1H), 7.76 (dd, J=2.0, 8.6 Hz, 1H), 6.99 (d, J=8.8 Hz, 1H), 5.21 (bs, 1H), 4.43-4.38 (m, 2H), 4.20-4.14 (m, 2H), 3.9 (s, 3H), 2.89 (s, 2H), 1.4 (s, 6H). MS: 374 [M++1].

Reference： [1]Patent: US2011/269244,2011,A1 .Location in patent: Page/Page column

19
[ 758684-29-6 ]
[ 1313994-06-7 ]

Reference： [1]Patent: US2011/269244,2011,A1

20
[ 758684-29-6 ]
[ 1313992-93-6 ]

Reference： [1]Patent: US2011/269244,2011,A1

21
[ 758684-29-6 ]
[ 1313992-92-5 ]

Reference： [1]Patent: US2011/269244,2011,A1

22
[ 758684-29-6 ]
[ 1343371-68-5 ]

Reference： [1]Patent: US2011/269244,2011,A1

23
[ 758684-29-6 ]
[ 1343371-63-0 ]

Reference： [1]Patent: US2011/269244,2011,A1

24
[ 758684-29-6 ]
[ 1343371-55-0 ]

Reference： [1]Patent: US2011/269244,2011,A1

25
[ 758684-29-6 ]
[ 1343370-01-3 ]

Reference： [1]Patent: US2011/269244,2011,A1

26
[ 758684-29-6 ]
[ 1313994-11-4 ]

Reference： [1]Patent: US2011/269244,2011,A1

27
[ 758684-29-6 ]
[ 59595-92-5 ]
4-(3,5-dichloro-4-hydroxybenzoyl)-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylic acid [ No CAS ]

Reference： [1]Patent: US2008/64871,2008,A1

28
[ 536-25-4 ]
[ 758684-29-6 ]

Reference： [1]Patent: US2008/64871,2008,A1

29
[ 758684-29-6 ]
[ 100-39-0 ]
4-benzyl-N-hydroxy-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamide [ No CAS ]

Reference： [1]Patent: WO2017/40963,2017,A1

30
[ 758684-29-6 ]
[ 100-39-0 ]
methyl 4-benzyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With potassium carbonate; In N,N-dimethyl-formamide; at 80℃;	Potassium carbonate (86 mg, 0.621 mmol) was added to a solution of methyl 3,4- dihydro-2H-benzo[b][l,4]oxazine-6-carboxylate (30 mg, 0.155 mmol) in DMF (2 mL). (Bromomethyl)benzene (0.028 mL, 0.233 mmol) was added, and the reaction was placed on a heater/shaker at 80 C overnight. The reaction mixture was cooled to room temperature, diluted with ethyl acetate, and washed with brine. The organic layer was separated and concentrated to afford methyl 4-benzyl-3,4-dihydro-2H-benzo[b][l,4]oxazine-6-carboxylate which was used directly in the next step without further purification. MS: (ES, m/z): 284 [M+H]+.

Reference： [1]Patent: WO2017/40963,2017,A1 .Location in patent: Paragraph 00317

31
[ 758684-29-6 ]
1-(6-(methoxycarbonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-4-carbonyl)-3-methyl-1H-imidazol-3-ium iodide [ No CAS ]

Reference： [1]Patent: WO2017/40963,2017,A1

32
[ 758684-29-6 ]
methyl 4-(piperidine-1-carbonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate [ No CAS ]

Reference： [1]Patent: WO2017/40963,2017,A1

33
[ 758684-29-6 ]
N-hydroxy-4-(piperidine-1-carbonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamide [ No CAS ]

Reference： [1]Patent: WO2017/40963,2017,A1

34
[ 758684-29-6 ]
[ 50824-05-0 ]
N-hydroxy-4-(4-(trifluoromethoxy)benzyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamide [ No CAS ]

Reference： [1]Patent: WO2017/40963,2017,A1

35
[ 758684-29-6 ]
[ 50824-05-0 ]
C₁₈H₁₆F₃NO₄ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With potassium carbonate; In N,N-dimethyl acetamide; at 50℃; for 16h;Sealed tube;	A half-dram vial was charged with methyl 3,4-dihydro-2H-benzo[b][l,4]oxazine-6- carboxylate (0.2 M in N,N-dimethylacetamide, 150 mu., 30 muiotaetaomicron) and potassium carbonate (20.7 mg, 150 muiotaetaomicron). Then a solution of l-(bromomethyl)-4-(trifluoromethoxy)benzene (0.2 M in N,N-di methyl acetamide, 400 mu., 80 muiotaetaomicron) was added. The system was sealed and shaken at 50 C for 16 h, and then the solvent was removed under a stream of nitrogen. The residue was diluted with ethyl acetate (0.6 mL) and brine (0.5 mL), and the mixture was shaken. The organic layer was separated, and the aqueous phase was extracted with ethyl acetate (0.6 mL). The combined organic layers were dried under a stream of nitrogen. THF/methanol (3 : 1, 200 mu.) was added to the residue. The vial was sealed and shaken at 50 C for 15 min to dissolve the residue, then cooled to room temperature. Hydroxylamine (150 mu., 50% v/v solution in water) was added, followed by 1 N aqueous sodium hydroxide solution (100 mu.). The mixture was sealed and then shaken at room temperature for 16 h. The reaction mixture was concentrated under a stream of nitrogen at room temperature, then dissolved in 500 mu^ of DMSO, and purified by mass triggered preparative HPLC (Column: Waters Sunfire CI 8, 5 mupiiota, 19x50 mm; Mobile Phase: water (0.1% formic acid) and acetonitrile (0.1% formic acid) (15% to 100% acetonitrile in 6 min; flow rate: 23 mL/min); Detector: UV 254/220 nm). The product-containing fractions were combined and concentrated in a Genevac to afford N-hydroxy-4-(4- (trifluoromethoxy)benzyl)-3,4-dihydro-2H-benzo[b][l,4]oxazine-6-carboxamide (6.7 mg, 60.6%). (ES, m/z) 369 [M+H]+, LC-MS Rt 1.35 min.

Reference： [1]Patent: WO2017/40963,2017,A1 .Location in patent: Paragraph 00266

36
[ 758684-29-6 ]
[ 110-62-3 ]
C₁₅H₂₁NO₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium tris(acetoxy)borohydride; In N,N-dimethyl acetamide; 1,2-dichloro-ethane; at 20℃; for 16h;Sealed tube;	A half-dram vial was charged with methyl 3,4-dihydro-2H-benzo[b][l,4]oxazine-6- carboxylate (0.2 M in N,N-dimethylacetamide, 150 mu., 30 muiotaetaomicron) and pentanal (0.2M in 1,2- dichloroethane, 300 muL, 60 muiotaetaomicron). A solution of sodium triacetoxyborohydride (0.2 M in 1,2- dichloroethane, 450 muIota_, , 90 muiotaetaomicron) was added, and the system was sealed and shaken at room temperature for 16 h. The solvent was removed under a stream of nitrogen, the residue was diluted with ethyl acetate (0.6 mL) and a solution of 1 N sodium hydroxide in brine (0.5 mL), and the mixture was shaken. The organic layer was separated and the aqueous phase was extracted with ethyl acetate (0.6 mL). The combined organic layers were dried under a stream of nitrogen. THF/methanol (3 : 1, 200 mu.) was added to the residue. The vial was sealed and shaken at 50 C for 15 minutes to dissolve the residue, then cooled to room temperature. Hydroxylamine (150 mu., 50% v/v solution in water) was added, followed by 1 N aqueous sodium hydroxide solution (100 mu.). The mixture was sealed and then shaken at room temperature for 16 h. The reaction mixture was concentrated under a stream of nitrogen at room temperature, dissolved in 500 muIota_, of DMSO, and purified by mass triggered preparative HPLC (Column: Waters Sunfire C18, 5 mupiiota, 19x50 mm; Mobile Phase: water (0.1% formic acid) and acetonitrile (0.1% formic acid) (15% to 100% acetonitrile in 6 min; flow rate: 23 mL/min); Detector: UV 254/220 nm). The product-containing fractions were combined and concentrated in a Genevac to afford N- hydroxy-4-pentyl-3,4-dihydro-2H-benzo[b][l,4]oxazine-6-carboxamide (1.3 mg, 16%). (ES, m/z) 265 [M+H]+, LC-MS Rt 1.20 min.

Reference： [1]Patent: WO2017/40963,2017,A1 .Location in patent: Paragraph 00270

37
[ 758684-29-6 ]
[ 110-62-3 ]
N-hydroxy-4-pentyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamide [ No CAS ]

Reference： [1]Patent: WO2017/40963,2017,A1

38
[ 758684-29-6 ]
[ 98-09-9 ]
methyl 4-(phenylsulfonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; In acetonitrile; at 20℃;	Benzenesulfonyl chloride (43.9 mg, 0.248 mmol) and N,N-diisopropylethylamine (0.108 mL, 0.621 mmol) were added to a solution of methyl 3,4-dihydro-2H- benzo[b][l,4]oxazine-6-carboxylate (40 mg, 0.207 mmol) in acetonitrile (2 mL), and the reaction stirred at ambient temperature overnight. The reaction was diluted with ethyl acetate and washed with brine. The organic phase was separated and concentrated to afford methyl 4- (phenylsulfonyl)-3,4-dihydro-2H-benzo[b][l,4]oxazine-6-carboxylate which was used directly in the next step without further purification. MS: (ES, m/z): 366 [M+S+H]+.

Reference： [1]Patent: WO2017/40963,2017,A1 .Location in patent: Paragraph 00277

39
[ 758684-29-6 ]
[ 98-09-9 ]
N-hydroxy-4-(phenylsulfonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamide [ No CAS ]

Reference： [1]Patent: WO2017/40963,2017,A1

40
[ 758684-29-6 ]
[ 530-62-1 ]
methyl 4-(1H-imidazole-1-carbonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In tetrahydrofuran; at 80℃; for 192h;	A solution of methyl 3,4-dihydro-2H-benzo[b][l,4]oxazine-6-carboxylate (300 mg, 1.55 mmol) and carbonyl diimidazole (277 mg, 1.708 mmol) in THF (10 mL) was heated at 80C for 8 days. The reaction was cooled to ambient temperature and then concentrated to dryness. The residue was diluted with dichloromethane and washed with brine. The organic layer was passed through an Isolute phase separator and then concentrated to afford methyl 4-(lH- imidazole-l-carbonyl)-3,4-dihydro-2H-benzo[b][l,4]oxazine-6-carboxylate which was used directly in the next step without further purification. MS: (ES, m/z): 288 [M+H]+.

Reference： [1]Patent: WO2017/40963,2017,A1 .Location in patent: Paragraph 00283

41
[ 758684-29-6 ]
[ 123-11-5 ]
N-hydroxy-4-(4-methoxybenzyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamide [ No CAS ]

Reference： [1]Patent: WO2017/40963,2017,A1

42
[ 758684-29-6 ]
[ 123-11-5 ]
methyl 4-(4-methoxybenzyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		4-Methoxybenzaldehyde (31.5 mu,, 0.259 mmol) and acetic acid (50 0.873 mmol) were added to a solution of methyl 3,4-dihydro-2H-benzo[b][l,4]oxazine-6-carboxylate (50.0 mg, 0.259 mmol) in 1,2-dichloroethane (2 mL), and the reaction mixture was placed on a heater/shaker at 50 C for 2 hours. Sodium triacetoxyborohydride (137 mg, 0.647 mmol) was added, and the reaction was placed on the heater/shaker at 50 C overnight. The reaction was diluted with dichloromethane, washed with brine, and passed through an Isolute phase separator. The filtrate was concentrated and purified by column chromatography on silica gel (Biotage 10 gram column, eluting with 10-60% ethyl acetate-hexanes) to afford methyl 4-(4- methoxybenzyl)-3,4-dihydro-2H-benzo[b][l,4]oxazine-6-carboxylate which was used directly in the next step MS: (ES, m/z): 314 [M+H]+.

Reference： [1]Patent: WO2017/40963,2017,A1 .Location in patent: Paragraph 00315

43
[ 758684-29-6 ]
[ 98-88-4 ]
4-benzoyl-N-hydroxy-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamide [ No CAS ]

Reference： [1]Patent: WO2017/40963,2017,A1

44
[ 758684-29-6 ]
[ 98-88-4 ]
methyl 4-benzoyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; In 1,2-dichloro-ethane; at 20℃;	Triethylamine (0.065 mL, 0.466 mmol) and benzoyl chloride (0.022 mL, 0.186 mmol) were added to a solution of methyl 3,4-dihydro-2H-benzo[b][l,4]oxazine-6-carboxylate (30 mg, 0.155 mmol) in 1,2-dichloroethane (2mL), and the reaction stirred at ambient temperature overnight. The reaction was diluted with dichloromethane and washed with brine. The organic layer was passed through an Isolute phase separator, and then concentrated to afford a quantitative yield of methyl 4-benzoyl-3,4-dihydro-2H-benzo[b][l,4]oxazine-6- carboxylate which was used directly in the next step without further purification. MS: (ES, m/z): 298 [M+H]+.

Reference： [1]Patent: WO2017/40963,2017,A1 .Location in patent: Paragraph 00320

45
[ 758684-29-6 ]
[ 79455-63-3 ]
methyl 4-(2-chloro-6-fluorobenzoyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
64%	With triethylamine In dichloromethane at 20℃; for 2h;	Methyl 4-(2-chloro-6-fluorobenzoyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate To a stirred solution of methyl 3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (200 mg,1.096 mmol) in DCM (5 mL) was added TEA (0.299 mL, 2.07 mmol) followed by 2-chloro-6-fluorobenzoyl chloride (0.145 mL, 1.139 mmol) and stirred at RT for 2 h. TLC showedcompletion of the reaction, at which point the solvent was evaporated and the crude productwas purified by Combi-flash to afford the title compound (230 mg, 64% yield) as a whitesolid.

Reference： [1]Pryde, David C.; Middya, Sandip; Banerjee, Monali; Shrivastava, Ritesh; Basu, Sourav; Ghosh, Rajib; Yadav, Dharmendra B.; Surya, Arjun [European Journal of Medicinal Chemistry, 2021, vol. 209]

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 758684-29-6 ]

Esters

[ 142166-01-6 ]

Methyl 3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carboxylate

Similarity: 0.97

[ 121591-81-9 ]

Methyl 3,4-dihydro-2H-benzo[b][1,4]oxazine-5-carboxylate

Similarity: 0.96

[ 1190198-13-0 ]

Methyl 7-(benzyloxy)-1H-indole-5-carboxylate

Similarity: 0.92

[ 24812-90-6 ]

Methyl 3-amino-4-methoxybenzoate

Similarity: 0.86

[ 681465-85-0 ]

Methyl 4-amino-3-isopropoxybenzoate

Similarity: 0.83

Related Parent Nucleus of
[ 758684-29-6 ]

Other Aromatic Heterocycles

[ 142166-01-6 ]

Methyl 3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carboxylate

Similarity: 0.97

[ 121591-81-9 ]

Methyl 3,4-dihydro-2H-benzo[b][1,4]oxazine-5-carboxylate

Similarity: 0.96

[ 134997-87-8 ]

3-Oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylic acid

Similarity: 0.88

[ 141103-93-7 ]

4-Methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carbaldehyde

Similarity: 0.82

[ 1092352-65-2 ]

2-Methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylic acid

Similarity: 0.81

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 758684-29-6 ] {[proInfo.proName]}

Quality Control of [ 758684-29-6 ]

Related Doc. of [ 758684-29-6 ]

Product Details of [ 758684-29-6 ]

Calculated chemistry of [ 758684-29-6 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 758684-29-6 ]

Application In Synthesis of [ 758684-29-6 ]

[ 758684-29-6 ] Synthesis Path-Upstream 1~7

[ 758684-29-6 ] Synthesis Path-Downstream 1~45

Related Functional Groups of [ 758684-29-6 ]

Esters

Related Parent Nucleus of [ 758684-29-6 ]

Other Aromatic Heterocycles

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 758684-29-6 ]

Related Parent Nucleus of
[ 758684-29-6 ]